Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Mar 31, 2026, 20:49 ET The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
but it also highlights the manufacturing complexity: each treatment is custom-made from the patient's own tumor tissue. Denali Therapeutics (NASDAQ: DNLI) is advancing tividenofusp alfa for Hunter syndrome, with a PDUFA target date of April 2026 and Fast Track, Breakthrough Therapy, and Priority Medicines
More news about: USA News Group
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
patient's own tumor tissue — underscoring how critical scalable cellular infrastructure is to the future of the field. Denali Therapeutics (NASDAQ: DNLI) is advancing tividenofusp alfa for Hunter syndrome, with a PDUFA target date of April 2026 and multiple FDA designations, requiring precise protein
More news about: USA News Group